New Drugs for Bacillus Calmette Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer
10.22465/kjuo.2022.20.1.12
- Author:
Jaewoon JEONG
1
;
Jae Baek HA
;
In Ho CHANG
Author Information
1. College of Medicine, Chung-Ang University, Seoul, Korea
- Publication Type:Review Article
- From:Korean Journal of Urological Oncology
2022;20(1):12-24
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
For intermediate- and high-risk nonmuscle invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment following transurethral resection of bladder tumor. Although intravesical BCG therapy improves disease progression and bladder preservation in most patients, there are still a considerable number of BCG-unresponsive cases, for whom radical cystectomy (RC) is the recommended salvage treatment option. However, RC is associated with high morbidity and mortality rates, and alternative treatment options are needed. New approaches, such as intravesical chemotherapy, device-assisted treatments, immune checkpoint inhibitors, viral gene therapy, antibody-drug conjugates, fibroblast growth factor receptor inhibitors, and other novel agents are being investigated. This review aims to provide an overview of the recent trials for BCG-unresponsive NMIBC.
